Key facts
- Notable investors include MPower Partners, Pola Orbis Holdings.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for TAZ (Biotechnology)
- ·The full record, as it builds
Funding rounds
No funding rounds for TAZ (Biotechnology) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About TAZ (Biotechnology)
Operator of a longevity-focused biotechnology company intended to extend healthy lifespans by addressing aging-related challenges through science and innovation. The company offers proprietary anti-aging services, including senescent cell removal technologies, epigenetic age analysis services and drug discovery pipelines, enabling customers such as healthcare providers, researchers and consumers to improve healthspan, reduce age-related disease risks and access personalized longevity-enhancing products.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2020
- Website
- taz-co.jp/
- Ownership
- Privately Held (backing)
TAZ (Biotechnology) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in TAZ (Biotechnology) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on TAZ (Biotechnology) in its N-PORT filings yet. We sweep new filings monthly.